Skip to nav Skip to content
  • Cancer Type: Breast
  • Study Type: Treatment
  • NCT#: NCT07174336
  • Phase: Phase II/III
Learn More
  • Overview

    Study Title:

    A Phase 2, Randomized, Open-Label Dose Optimization and Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of Tersolisib (LY4064809) Combined with a CDK4/6 Inhibitor and Endocrine Therapy in Adults with HR+, HER2- Advanced Breast Cancer with a PIK3CA Mutation Who Received No Prior Treatment for Advanced Breast Cancer (PIKALO-2)

  • Treatments

    Therapies:

    Allosteric, small-molecule, pan-mutant-selective PI3K-alpha inhibitor; Aromatase Inhibitor; CDK4/6 Inhibitor; Selective estrogen receptor degrader, SERD

    Medications:

    772256 (Palbociclib); Abemaciclib (); Anastrozole (); Arimadex (Anastrozole); Aromasin (Exemestane); Exemestane (); Faslodex (fulvestrant); Femara (Letrozole); LEE011 (Ribociclib); LY2835219 (Abemaciclib); Letrozole (); Palbociclib (); Ribociclib (); Tersolisib (); Tersolisib/Placebo (); fulvestrant ()

If you are interested in learning more about clinical trials, our clinical trial navigators can discuss your options and recommend opportunities that may be suitable for you. Call 813-745-6100 or 1-800-679-0775 (toll-free) or submit a clinical trials inquiry form.

Clinical Trial Search